Production (Stage)
Spero Therapeutics, Inc.
SPRO
$2.35
$1.67244.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -60.95% | 11.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -60.95% | 11.69% | |||
| Cost of Revenue | -85.29% | 13,059.46% | |||
| Gross Profit | 87.61% | -588.98% | |||
| SG&A Expenses | -3.29% | 35.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.08% | 11.95% | |||
| Operating Income | 30.18% | -12.13% | |||
| Income Before Tax | 32.68% | -18.13% | |||
| Income Tax Expenses | -- | 200.00% | |||
| Earnings from Continuing Operations | 33.62% | -21.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.62% | -21.82% | |||
| EBIT | 30.18% | -12.13% | |||
| EBITDA | 30.18% | -12.13% | |||
| EPS Basic | 34.62% | -20.90% | |||
| Normalized Basic EPS | 31.64% | -12.21% | |||
| EPS Diluted | 34.81% | -21.24% | |||
| Normalized Diluted EPS | 31.64% | -12.21% | |||
| Average Basic Shares Outstanding | 1.54% | 0.76% | |||
| Average Diluted Shares Outstanding | 1.54% | 0.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||